JP2023533616A - Ｍｎｋ阻害を示すピリジン－１，５－ジオン及びそれらの使用方法 - Google Patents

Ｍｎｋ阻害を示すピリジン－１，５－ジオン及びそれらの使用方法 Download PDF

Info

Publication number
JP2023533616A
JP2023533616A JP2023524490A JP2023524490A JP2023533616A JP 2023533616 A JP2023533616 A JP 2023533616A JP 2023524490 A JP2023524490 A JP 2023524490A JP 2023524490 A JP2023524490 A JP 2023524490A JP 2023533616 A JP2023533616 A JP 2023533616A
Authority
JP
Japan
Prior art keywords
compound
alkyl
cycloalkyl
mmol
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023524490A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023533616A5 (https=
Inventor
セオドア ジェイ． プライス，
ジェイムズ ジェイ． サーン，
Original Assignee
４イー セラピューティクス， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ４イー セラピューティクス， インコーポレイテッド filed Critical ４イー セラピューティクス， インコーポレイテッド
Publication of JP2023533616A publication Critical patent/JP2023533616A/ja
Publication of JP2023533616A5 publication Critical patent/JP2023533616A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/20—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/14—Ortho-condensed systems
    • C07D491/147—Ortho-condensed systems the condensed system containing one ring with oxygen as ring hetero atom and two rings with nitrogen as ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/20—Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Epidemiology (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyridine Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Steroid Compounds (AREA)
  • Cosmetics (AREA)
JP2023524490A 2020-06-30 2021-06-30 Ｍｎｋ阻害を示すピリジン－１，５－ジオン及びそれらの使用方法 Pending JP2023533616A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063046325P 2020-06-30 2020-06-30
US63/046,325 2020-06-30
PCT/US2021/039982 WO2022006331A2 (en) 2020-06-30 2021-06-30 Pyridine-1,5-diones exhibitng mnk inhibition and their method of use

Publications (2)

Publication Number Publication Date
JP2023533616A true JP2023533616A (ja) 2023-08-03
JP2023533616A5 JP2023533616A5 (https=) 2024-06-26

Family

ID=79315594

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023524490A Pending JP2023533616A (ja) 2020-06-30 2021-06-30 Ｍｎｋ阻害を示すピリジン－１，５－ジオン及びそれらの使用方法

Country Status (11)

Country Link
US (1) US20230286983A1 (https=)
EP (1) EP4171565A4 (https=)
JP (1) JP2023533616A (https=)
KR (1) KR20230041715A (https=)
CN (1) CN116194112A (https=)
AU (1) AU2021300363A1 (https=)
BR (1) BR112022026275A2 (https=)
CA (1) CA3183551A1 (https=)
IL (1) IL299512A (https=)
MX (1) MX2022016516A (https=)
WO (1) WO2022006331A2 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3225747A1 (en) * 2021-06-30 2023-01-05 4E Therapeutics, Inc. Spirocyclic pyridine-1,5-diones exhibiting mnk inhibition and their method of use
EP4646266A1 (en) * 2023-01-04 2025-11-12 4E Therapeutics, Inc. Solid state forms of mnk inhibitors
WO2026006417A1 (en) * 2024-06-26 2026-01-02 4E Therapeutics, Inc. Formulations of mnk inhibitors

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015511638A (ja) * 2012-03-30 2015-04-20 エージェンシー フォー サイエンス，テクノロジー アンド リサーチ Ｍｎｋ１およびｍｎｋ２調節剤としての二環式ヘテロアリール誘導体、およびその使用
US20150376181A1 (en) * 2014-06-25 2015-12-31 Effector Therapeutics, Inc. Mnk inhibitors and methods related thereto
JP2018531266A (ja) * 2015-10-22 2018-10-25 セルビタ エス．エー． ピリドン誘導体およびキナーゼ阻害剤としてのその使用
WO2018218038A1 (en) * 2017-05-24 2018-11-29 Effector Therapeutics, Inc. Methods and compositions for cellular immunotherapy
JP2019510061A (ja) * 2016-03-31 2019-04-11 サウス オーストラリアン ヘルス アンド メディカル リサーチ インスティテュート リミテッドＳｏｕｔｈ Ａｕｓｔｒａｌｉａｎ Ｈｅａｌｔｈ Ａｎｄ Ｍｅｄｉｃａｌ Ｒｅｓｅａｒｃｈ Ｉｎｓｔｉｔｕｔｅ Ｌｉｍｉｔｅｄ 高脂肪食関連疾患を阻害する方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5575274B2 (ja) * 2010-02-26 2014-08-20 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 医薬組成物のためのｍｎｋｌ／ｍｎｋ２阻害活性を有する４−［シクロアルキルオキシ（ヘテロ）アリールアミノ］チエノ「２，３−ｄ］ピリミジン
CN103874496A (zh) * 2011-08-22 2014-06-18 默沙东公司 作为bace抑制剂的2-螺-取代的亚氨基噻嗪类及其单和二氧化物、组合物及其用途
BR112018008711A2 (pt) * 2015-10-29 2018-10-30 Effector Therapeutics Inc compostos de pirrolo-, pirazolo-, imidazo-pirimidina e piridina que inibem mnk1 e mnk2
GB201520500D0 (en) * 2015-11-20 2016-01-06 Medical Res Council Technology Compounds
CN113286592A (zh) * 2018-10-24 2021-08-20 效应治疗股份有限公司 Mnk抑制剂的结晶形式
CN111484494B (zh) * 2019-01-29 2022-09-13 诺沃斯达药业(上海)有限公司 抑制mnk1和mnk2的多环化合物
EP3972593B1 (en) * 2019-05-23 2025-07-02 Board of Regents, The University of Texas System Inhibitor of mnk for the treatment of neuropathic pain
CN110256432A (zh) * 2019-06-27 2019-09-20 诺沃斯达药业有限公司 抑制mnk1和mnk2的多环化合物

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015511638A (ja) * 2012-03-30 2015-04-20 エージェンシー フォー サイエンス，テクノロジー アンド リサーチ Ｍｎｋ１およびｍｎｋ２調節剤としての二環式ヘテロアリール誘導体、およびその使用
US20150376181A1 (en) * 2014-06-25 2015-12-31 Effector Therapeutics, Inc. Mnk inhibitors and methods related thereto
JP2017519782A (ja) * 2014-06-25 2017-07-20 イーフェクター セラピューティクス， インコーポレイテッド Ｍｎｋ阻害薬およびそれに関連する方法
JP2018531266A (ja) * 2015-10-22 2018-10-25 セルビタ エス．エー． ピリドン誘導体およびキナーゼ阻害剤としてのその使用
JP2019510061A (ja) * 2016-03-31 2019-04-11 サウス オーストラリアン ヘルス アンド メディカル リサーチ インスティテュート リミテッドＳｏｕｔｈ Ａｕｓｔｒａｌｉａｎ Ｈｅａｌｔｈ Ａｎｄ Ｍｅｄｉｃａｌ Ｒｅｓｅａｒｃｈ Ｉｎｓｔｉｔｕｔｅ Ｌｉｍｉｔｅｄ 高脂肪食関連疾患を阻害する方法
WO2018218038A1 (en) * 2017-05-24 2018-11-29 Effector Therapeutics, Inc. Methods and compositions for cellular immunotherapy

Also Published As

Publication number Publication date
CA3183551A1 (en) 2022-01-06
WO2022006331A3 (en) 2022-02-10
EP4171565A2 (en) 2023-05-03
EP4171565A4 (en) 2024-11-27
CN116194112A (zh) 2023-05-30
US20230286983A1 (en) 2023-09-14
MX2022016516A (es) 2023-03-28
KR20230041715A (ko) 2023-03-24
WO2022006331A9 (en) 2022-03-03
WO2022006331A8 (en) 2023-03-16
WO2022006331A2 (en) 2022-01-06
IL299512A (en) 2023-02-01
AU2021300363A1 (en) 2023-02-09
BR112022026275A2 (pt) 2023-03-14

Similar Documents

Publication Publication Date Title
US12110292B2 (en) Ligands to cereblon (CRBN)
US9314468B2 (en) Chemokine receptor modulators
US20260027217A1 (en) Degraders that target alk and therapeutic uses thereof
US12030892B2 (en) CRBN modulators
US20230158157A1 (en) Potent and selective degraders of alk
US20250205244A1 (en) Methods of treating migraine with mnk inhibitors
US20220241425A1 (en) Small molecule target bromo/acetyl proteins and uses thereof
JP2023533616A (ja) Ｍｎｋ阻害を示すピリジン－１，５－ジオン及びそれらの使用方法
US20240277852A1 (en) Inhibitors and degraders of pip4k protein
US20240400551A1 (en) Nek7 inhibitors
US20250177382A1 (en) Nek7 inhibitors
CA3214360A1 (en) Pyrimidine derivatives useful as lrrk2 kinase inhibitors
CN117597346A (zh) Nek7抑制剂
US20230226196A1 (en) Compounds for targeted degradation of interleukin-2-inducible t-cell kinase and methods of use
TW202523670A (zh) Ｐｄｅ ７調節劑化合物

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230301

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240618

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240618

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20250515

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250701

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250930

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251201

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260227